Salarius Pharmaceuticals, LLC

2450 Holcombe Blvd Ste J-608, Houston, Texas, United States

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

75.0%

Early Phase 1

25.0%

Trial Status Distribution

Active, not recruiting

25.0%

Completed

25.0%

Enrolling By Invitation

25.0%

Not yet recruiting

25.0%

Clinical Trials

Trials sponsored by this organization (4)

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

Early Phase 1

Not yet recruiting

interventional

Mar 202472 participants

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Phase 1

Enrolling By Invitation

interventional

Jan 202210 participants

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Phase 1

Completed

interventional

Jun 201923 participants

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1

Active, not recruiting

interventional

Jun 201850 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations